Neuroxelin (48mg)
Neuroxelin is a synthetic neuroprotective peptide designed to support neuroprotection and cognitive recovery following traumatic brain injury or stroke. It may reduce excitotoxic damage, modulate neuroinflammation, and support neural repair. Once-daily subcutaneous administration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Neuroxelin intervenes in the brain injury cascade via multiple mechanisms. It may reduce excitotoxic neuronal death by disrupting NMDA receptor signaling pathways, similar to nerinetide (NA-1). Additionally, it may reduce neuroinflammation by decreasing microglial activation and cytokine release. The peptide may also provide neurotrophic support by promoting synaptic repair and neurogenesis.
Quick Start
- Reconstitution: Add 3.0 mL bacteriostatic water → 16 mg/mL concentration.
- Typical daily range: 250–1000 mcg once daily (typical dose: 500 mcg).
- Storage: Lyophilized: −20 °C; reconstituted: 2–8 °C; use within 4 weeks.
Titration Approach (3 mL = 16 mg/mL)
Route: Subcutaneous | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 500 mcg | 3.1 Units (0.03 mL) |
| Weeks 5–8 | 750 mcg | 4.7 Units (0.05 mL) |
Studies report administration once daily subcutaneously, preferably in the morning. For doses ≤10 units use a 30 or 50-unit syringe.
Related compounds
Reconstitution Steps
- Let vial reach room temperature before opening.
- Draw up 3.0 mL of bacteriostatic water.
- Inject slowly down the side of the vial; avoid foaming.
- Swirl gently until dissolved (do not shake).
- Note concentration (16 mg/mL) and date; refrigerate at 2–8 °C.
Protocol Overview
- Goal: Neuroprotection, reduction of neuroinflammation, and enhancement of cognitive recovery.
- Schedule: Daily subcutaneous injections for 8–12 weeks.
- Storage: Lyophilized: −20 °C; reconstituted: 2–8 °C, use within 4 weeks.
Dosing Protocol
- Start: 500 mcg daily for Weeks 1–4; assess tolerance.
- Titration: Increase to 750–1000 mcg daily from Week 5 if tolerated.
- Frequency: Once daily (subcutaneously), preferably in the morning.
- Cycle Duration: 8–12 weeks; reassess every 8 weeks.
- Break between cycles: 4-week pause before repeating the cycle.
Washout & Cycle Restart
When can I restart?
4-week pause before repeating the cycle.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C in dry, dark conditions; stable for months.
- Reconstituted: 2–8 °C; use within 4 weeks; avoid freeze-thaw cycles.
- Allow vials to reach room temperature before opening.
Important Notes
Potential Benefits & Side Effects
Potential Benefits:
- Improved neurological outcomes after stroke or injury
- Improvement in cognitive scores (MoCA) at 90–360 days
- Reduced neuronal death and microglial activation in animal models
- Low toxicological profile in related Phase III peptides
Potential Side Effects:
- Potential mild local injection site reactions (redness, irritation)
- Related peptides showed no significant difference in adverse events vs. placebo
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Limited human safety data
Neuroxelin is a research neuroprotective peptide without completed clinical trials. Long-term human safety remains unknown. Related peptides (nerinetide) showed no significant adverse effects in Phase 3.
📄 ESCAPE-NA1 Trial — Lancet 2020References
- The Lancet – Nerinetide (ESCAPE-NA1) — Efficacy and safety of nerinetide in acute ischemic stroke – Phase 3 RCT
View Source - Scientific Reports (Nature) – CN-105 — Neuroprotective penta-peptide CN-105 reduces inflammation in a TBI model
View Source - Drugs (Springer) – Sovateltide — Efficacy of sovateltide in acute ischemic stroke – Phase III
View Source - Nutrients (PMC) – N-Pep-12 — Neuropsychological performance after N-Pep-12 in ischemic stroke (12 months)
View Source
Recommended Supplements
Omega-3 DHA
Lion's Mane (Hericium erinaceus)
Phosphatidylserine
External Sources & Regulatory Status
Regulatory Approvals
Research-only — Neuroprotective peptide (preclinical/investigational)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →